Product Information

IMATINIB MESYLATE 100 MG TAB is a generic product labeled by Upsher-Smith Laboratories LLC, priced at $0.6442 per EA under NDC 00832053209. Its NADAC has been published 110 times since Oct 9, 2024.

FDA first approved this application on Jun 21, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

IMATINIB MESYLATE 100 MG TAB

imatinib mesylate
$0.6442per EA

Strength

100 mg/1

NDC

00832053209

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

10/21/2026

Active Ingredients

IMATINIB MESYLATE

Approval Type

Generic (ANDA)

FDA Application

ANDA212135

FDA Approved

6/21/2022

TE Code

AB

On Market Since

5/17/2024

Pharmacological Classes

Bcr-Abl Tyrosine Kinase Inhibitors
Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A4 Inhibitors
Kinase Inhibitor

Price Statistics

The NADAC for IMATINIB MESYLATE 100 MG TAB has been published 110 times since Oct 9, 2024, and over the history we have for it it has risen 28.8%. The table below summarizes its recorded NADAC range and movement.

Current price$0.6442 per EA
All-time high$0.9761 (Sep 10, 2025)
All-time low$0.5002 (Oct 9, 2024)
52-week high$0.8736
52-week low$0.6114
Median price$0.7940
Average price$0.7719
Largest weekly change+17.0% (Nov 20, 2024)
Weeks tracked110
Tracking sinceOct 9, 2024

Price History

1W

0.0%

1M

+3.2%

3M

+4.3%

6M

-18.9%

1Y

-27.6%

3Y

N/A

5Y

N/A

All

+28.8%

Generic Alternatives

The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 24% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of IMATINIB MESYLATE 100 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 100 MG TAB, manufactured by Upsher-Smith Laboratories LLC, is $0.6442 per EA (NDC 00832053209), effective Nov 11, 2026.

How has the price of IMATINIB MESYLATE 100 MG TAB changed over time?

Over the history we have for it, the NADAC for IMATINIB MESYLATE 100 MG TAB has risen 28.8%. It has been tracked across 110 weekly CMS publications since Oct 9, 2024.

What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 100 MG TAB?

Since Oct 9, 2024, the NADAC for IMATINIB MESYLATE 100 MG TAB has ranged from a low of $0.5002 (Oct 9, 2024) to a high of $0.9761 (Sep 10, 2025), with a median of $0.7940 per EA.

Are there cheaper alternatives to IMATINIB MESYLATE 100 MG TAB?

Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IMATINIB MESYLATE 100 MG TAB, is $0.4912 per EA — about 24% below IMATINIB MESYLATE 100 MG TAB.

Who manufactures IMATINIB MESYLATE 100 MG TAB?

IMATINIB MESYLATE 100 MG TAB (NDC 00832053209) is labeled by Upsher-Smith Laboratories LLC, and CMS classifies it as a generic product.